Literature DB >> 25575627

The double-edged sword of AMPK signaling in cancer and its therapeutic implications.

Sang-Min Jeon1, Nissim Hay.   

Abstract

5'-AMP-activated protein kinase (AMPK) plays a pivotal role in maintaining energy and redox homeostasis under various metabolic stress conditions. Metabolic adaptation, which can be triggered by the activation of AMPK during metabolic stress, is the critical process for cell survival through the maintenance of ATP and NADPH levels. The importance of such regulation of fundamental process poses the AMPK signaling pathway in one of the most attractive therapeutic targets in many pathologies such as diabetes and cancer. In cancer, however, accumulating data suggest that the role of AMPK would not be simply defined as anti- or pro-tumorigenic, but it seems to have two faces like a double-edged sword. Importantly, recent studies showed that the anti-tumorigenic effects of many 'indirect' AMPK activators such as anti-diabetic biguanides are not dependent on AMPK; rather the activation of AMPK induces the resistance to their cytotoxic effects, emphasizing the pro-tumorigenic effect of AMPK. In this review, we summarize and discuss recent findings suggesting the two faces of AMPK in cancer, and discuss how we can exploit this unique feature of AMPK for novel therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25575627      PMCID: PMC5789788          DOI: 10.1007/s12272-015-0549-z

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  85 in total

Review 1.  Potential applications for biguanides in oncology.

Authors:  Michael Pollak
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  AMP as a low-energy charge signal autonomously initiates assembly of AXIN-AMPK-LKB1 complex for AMPK activation.

Authors:  Ya-Lin Zhang; Huiling Guo; Chen-Song Zhang; Shu-Yong Lin; Zhenyu Yin; Yongying Peng; Hui Luo; Yuzhe Shi; Guili Lian; Cixiong Zhang; Mengqi Li; Zhiyun Ye; Jing Ye; Jiahuai Han; Peng Li; Jia-Wei Wu; Sheng-Cai Lin
Journal:  Cell Metab       Date:  2013-10-01       Impact factor: 27.287

3.  MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells.

Authors:  Jakub Godlewski; Michal O Nowicki; Agnieszka Bronisz; Gerard Nuovo; Jeff Palatini; Michael De Lay; James Van Brocklyn; Michael C Ostrowski; E Antonio Chiocca; Sean E Lawler
Journal:  Mol Cell       Date:  2010-03-12       Impact factor: 17.970

4.  Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

Authors:  Isaam Ben Sahra; Claire Regazzetti; Guillaume Robert; Kathiane Laurent; Yannick Le Marchand-Brustel; Patrick Auberger; Jean-François Tanti; Sophie Giorgetti-Peraldi; Frédéric Bost
Journal:  Cancer Res       Date:  2011-05-03       Impact factor: 12.701

5.  5'-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors.

Authors:  Keith R Laderoute; Joy M Calaoagan; Wan-Ru Chao; Dominc Dinh; Nicholas Denko; Sarah Duellman; Jessica Kalra; Xiaohe Liu; Ioanna Papandreou; Lidia Sambucetti; Laszlo G Boros
Journal:  J Biol Chem       Date:  2014-07-03       Impact factor: 5.157

6.  A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF.

Authors:  V Borgdorff; U Rix; G E Winter; M Gridling; A C Müller; F P Breitwieser; C Wagner; J Colinge; K L Bennett; G Superti-Furga; S N Wagner
Journal:  Oncogene       Date:  2013-06-03       Impact factor: 9.867

7.  Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.

Authors:  Cristina M Contreras; Sushma Gurumurthy; J Marshall Haynie; Lane J Shirley; Esra A Akbay; Shana N Wingo; John O Schorge; Russell R Broaddus; Kwok-Kin Wong; Nabeel Bardeesy; Diego H Castrillon
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

8.  Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells.

Authors:  Enza Lonardo; Michele Cioffi; Patricia Sancho; Yolanda Sanchez-Ripoll; Sara Maria Trabulo; Jorge Dorado; Anamaria Balic; Manuel Hidalgo; Christopher Heeschen
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

9.  The dark face of AMPK as an essential tumor promoter.

Authors:  Sang-Min Jeon; Nissim Hay
Journal:  Cell Logist       Date:  2012-10-01

10.  AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation.

Authors:  Graeme J Gowans; Simon A Hawley; Fiona A Ross; D Grahame Hardie
Journal:  Cell Metab       Date:  2013-10-01       Impact factor: 27.287

View more
  44 in total

1.  Perspective: Do Fasting, Caloric Restriction, and Diets Increase Sensitivity to Radiotherapy? A Literature Review.

Authors:  Philippe Icard; Luc Ollivier; Patricia Forgez; Joelle Otz; Marco Alifano; Ludovic Fournel; Mauro Loi; Juliette Thariat
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

2.  Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification and network pharmacology.

Authors:  A S P Pereira; M J Bester; Z Apostolides
Journal:  Mol Divers       Date:  2017-09-18       Impact factor: 2.943

3.  Procyanidin B2 3,3″-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK.

Authors:  Rahul Kumar; Gagan Deep; Michael F Wempe; Joseph Surek; Amit Kumar; Rajesh Agarwal; Chapla Agarwal
Journal:  Mol Carcinog       Date:  2017-09-22       Impact factor: 4.784

Review 4.  Cell intrinsic and extrinsic regulation of leukemia cell metabolism.

Authors:  Yajian Jiang; Daisuke Nakada
Journal:  Int J Hematol       Date:  2016-02-20       Impact factor: 2.490

Review 5.  A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.

Authors:  Ayesha S Khan; Daniel E Frigo
Journal:  Nat Rev Urol       Date:  2017-02-01       Impact factor: 14.432

6.  AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow.

Authors:  Yusuke Saito; Richard H Chapple; Angelique Lin; Ayumi Kitano; Daisuke Nakada
Journal:  Cell Stem Cell       Date:  2015-10-01       Impact factor: 24.633

7.  AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965.

Authors:  Toby A Dite; Christopher G Langendorf; Ashfaqul Hoque; Sandra Galic; Richard J Rebello; Ashley J Ovens; Lisa M Lindqvist; Kevin R W Ngoei; Naomi X Y Ling; Luc Furic; Bruce E Kemp; John W Scott; Jonathan S Oakhill
Journal:  J Biol Chem       Date:  2018-04-25       Impact factor: 5.157

8.  Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.

Authors:  Dinoop Ravindran Menon; Sabrina Hammerlindl; Heinz Hammerlindl; Abdullah Al Emran; Joachim Torrano; Katrin Sproesser; Divya Thakkar; Min Xiao; Victoria G Atkinson; Brian Gabrielli; Nikolas K Haass; Meenhard Herlyn; Clemens Krepler; Helmut Schaider
Journal:  Clin Cancer Res       Date:  2017-12-01       Impact factor: 12.531

9.  Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors.

Authors:  Christopher J Matheson; Kimberly A Casalvieri; Donald S Backos; Mohammed Minhajuddin; Craig T Jordan; Philip Reigan
Journal:  Eur J Med Chem       Date:  2020-04-16       Impact factor: 6.514

10.  3-Acetyl-oleanolic acid ameliorates non-alcoholic fatty liver disease in high fat diet-treated rats by activating AMPK-related pathways.

Authors:  Qiong Ou-Yang; Chun-Xiao Xuan; Xue Wang; Han-Qiong Luo; Jin-E Liu; Lan-Lan Wang; Ting-Ting Li; Yu-Peng Chen; Jun Liu
Journal:  Acta Pharmacol Sin       Date:  2018-01-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.